Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis
Лекарственные препараты для лечения легочной артериальной гипертензии: систематический обзор и сетевой метаанализ
2022-08-10
SCID: 54.1/pp7cfzsj
Discuss with AI
endothelin receptor antagonistsnetwork meta-analysisphosphodiesterase-5 inhibitorspulmonary arterial hypertensionriociguat
Figures from the paper
Abstract (AI)
BACKGROUND: There is no consensus on the most effective treatments of pulmonary arterial hypertension (PAH). Our objective was to compare effects of medications for PAH. METHODS: We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and Clinicaltrials.gov from inception to December 2021. We performed a frequentist random-effects network meta-analysis on all included trials. We rated the certainty of the evidence using the Grades of Recommendation, Assessment, Development, and Evaluation approach. RESULTS: We included 53 randomised controlled trials with 10 670 patients. Combination therapy with endothelin receptor antagonist (ERA) plus phosphodiesterase-5 inhibitors (PDE5i) reduced clinical worsening (120.7 fewer events per 1000, 95% CI 136.8-93.4 fewer; high certainty) and was superior to either ERA or PDE5i alone, both of which reduced clinical worsening, as did riociguat monotherapy (all high certainty). PDE5i (24.9 fewer deaths per 1000, 95% CI 35.2 fewer to 2.1 more); intravenous/subcutaneous prostanoids (18.3 fewer deaths per 1000, 95% CI 28.6 fewer deaths to 0) and riociguat (29.1 fewer deaths per 1000, 95% CI 38.6 fewer to 8.7 more) probably reduce mortality as compared to placebo (all moderate certainty). Combination therapy with ERA+PDE5i (49.9 m, 95% CI 25.9-73.8 m) and riociguat (49.5 m, 95% CI 17.3-81.7 m) probably increase 6-min walk distance as compared to placebo (moderate certainty). CONCLUSION: Current PAH treatments improve clinically important outcomes, although the degree and certainty of benefit vary between treatments.
Key Findings
1
A systematic review and network meta-analysis included 53 randomized controlled trials involving 10,670 patients with pulmonary arterial hypertension.
2
Combination therapy with an endothelin receptor antagonist plus a phosphodiesterase-5 inhibitor substantially reduced clinical worsening and was superior to either monotherapy.
3
Endothelin receptor antagonist plus phosphodiesterase-5 inhibitor therapy and riociguat probably improved 6-minute walk distance by approximately 50 meters versus placebo.
4
Endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and riociguat monotherapy each reduced clinical worsening compared with placebo, with high-certainty evidence.
5
Phosphodiesterase-5 inhibitors, intravenous or subcutaneous prostanoids, and riociguat probably reduce mortality compared with placebo, although evidence certainty was moderate.
Research Object
Medications for pulmonary arterial hypertension
Research Subject
Comparative effects on clinical worsening, mortality, and 6-minute walk distance
Publication Details
Publication Date
2022-08-10
Journal
Publisher
ISSN
Cited by
32
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest